Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens

CompletedOBSERVATIONAL
Enrollment

257

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

June 6, 2022

Study Completion Date

June 6, 2022

Conditions
Pneumonia, BacterialPneumonia, ViralPneumonia FungalPneumonia CavitaryImmunocompromised Host
Interventions
DIAGNOSTIC_TEST

Karius Test

Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma

Trial Locations (10)

10021

Weill Cornell Medicine, New York

10065

Memorial Sloan Kettering Cancer Center, New York

15025

University of Pittsburgh, Pittsburgh

27710

Duke University, Durham

70112

Tulane Section of Infectious Disease, New Orleans

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado Denver, Aurora

91010

City of Hope Comprehensive Cancer Center, Duarte

94143

UCSF Department of Medicine, San Francisco

98109

Fred Hutchinson Cancer Center, Seattle

Sponsors
All Listed Sponsors
collaborator

Duke Clinical Research Institute

OTHER

lead

Karius, Inc.

INDUSTRY